In the Oncomine database, EpCAM expression was significantly higher in BLCA, breast cancer, cervical cancer, ESCA, STAD, HNSC, LIHC, lung cancer, ovarian cancer, and prostate adenocarcinoma (PRAD) but significantly lower in brain cancer, kidney cancer, leukemia, melanoma, and sarcoma than in normal tissues (Fig. 2B). Here, EPCAM is linked to prostate adenocarcinoma.